Skip to main content

Transoral robotic versus laser surgery for cT1-T3 supraglottic laryngeal cancers: a systematic review and meta-analysis of comparative and non-comparative studies

Journal
Oral oncology (Q1)
Published
15 October 2026
Study design
Systematic review of cohort studies
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Jerome R Lechien, Luigi A Vaira, Robin Baudouin, Pierre Guarino, Carlos M Chiesa-Estomba, Aliya Turayeva, et al.
PMID
42880162
DOI
10.1016/j.oraloncology.2026.108172

Why clinicians should know about it

  • Picked for Otorhinolaryngology (paper of the day, 19 October 2026): TORS vs laser outcomes for supraglottic cancer

Abstract

BACKGROUND: To compare literature findings about functional, oncological and surgical outcomes of transoral robotic (TORS) versus transoral laser microsurgery (TOLM) for supraglottic cT1-T3 laryngeal cancers. METHODS: Three independent investigators conducted a PubMed, Scopus, and Cochrane Library search for papers reporting oncological, functional and surgical (complications) outcomes of TOLM and TORS. Outcomes were statistically compared considering controlled (direct) studies, and indirectly between single-arm cohort studies. RESULTS: Fifty studies (2,644 patients) were included: 19 single-arm TORS (n = 615), 27 single-arm TOLM (n = 1,122), and four comparative studies (n = 907). Pooled positive margins were 7.3% (95%CI, 4.3-12.0) after TORS and 12.7% (8.6-18.3) after TOLM (P = 0.08); the comparative meta-analysis yielded a risk ratio of 0.65 (0.21-1.99; P = 0.45), also favoring TORS non-significantly. No difference was found for postoperative hemorrhage (5.8% versus 6.4%; P = 0.79) or permanent gastrostomy (7.4% versus 4.8%; P = 0.33). Permanent tracheostomy was rare in both groups (1.6% versus 1.3%), and laryngeal preservation reached 99.6% and 93.0%, respectively. Complication rates were not poolable for TOLM (I2 = 87.0%) owing to definitional heterogeneity. Five-year overall survival was 72.6% (65.8-78.4) in the TOLM series and not poolable for TORS. Median follow-up was 26 versus 50 months. CONCLUSION: TORS and TOLM provide currently comparable oncological, surgical, and functional outcomes in cT1-T3 supraglottic LSCC. Direct and indirect evidence converged toward a non-significant margin advantage for TORS. Apparent differences across the literature more plausibly reflect case mix, era, follow-up duration, and outcome definitions than the surgical technique itself. Randomized comparisons in matched populations are critically needed.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.